Executive Board
The Executive Board has been established to assist the Chief Executive in leading The Institute of Cancer Research to achieve its strategic aims and objectives within the approved strategies and budgets and is responsible for formulating strategies, plans and budgets for approval by the Board of Trustees.
Professor Kristian Helin
Chief Executive and President
Professor Kevin Harrington
Head of Division – Radiotherapy and Imaging
Professor Clare Isacke
Dean of Academic and Research Affairs
Paul Norris
Chief Financial Officer
Jonathan Monk
Chief Information Officer
Professor Jonathon Pines
Head of Division – Cell and Molecular Biology
Dr Barbara Pittam
Chief Research and Academic Officer
Dr Olivia Rossanese
Head of Division – Cancer Therapeutics
Dr Kary Kelly
Chief Development and Communications Officer
Latest ICR News
New trial design could improve early-stage cancer studies involving CAR-T therapies
Researchers have developed a new statistical approach that could help improve how early-stage cancer trials identify the safest and most effective doses of advanced therapies, such as CAR-T therapy.
Researchers develop gene-editing platform to systematically decode histone function in mammalian cells
Scientists have developed a powerful new gene-editing platform that allows them, for the first time, to systematically test the function of key proteins in mammalian cells.
New clinical trial design could improve dose selection, maximising treatment efficacy and safety
Researchers have developed a new approach to help determine the optimal dose of cancer drugs, aiming to make early-stage clinical trials more transparent and better aligned with patient needs.
The ICR and The Royal Marsden partner with Mint Medical on roll out of global AI cancer imaging tool
The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have announced a new licensing agreement with MedTech company Mint Medical, a Snke Company, to improve monitoring for patients with bone disease in advanced prostate cancer and multiple myeloma.